UNCY RSI Chart
Last 7 days
15.5%
Last 30 days
-18.8%
Last 90 days
20.4%
Trailing 12 Months
-9.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 882.0K | 813.0K | 744.0K | 675.0K |
2022 | 0 | 0 | 0 | 951.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jul 11, 2023 | aggarwal gaurav | acquired | - | - | 3,470,150 | - |
Jul 11, 2023 | gupta pramod | acquired | - | - | 41,845 | evp, pharmaceuticals and bd |
Jul 11, 2023 | gupta shalabh k. | acquired | - | - | 104,612 | ceo |
Jul 11, 2023 | jermasek douglas | acquired | - | - | 104,612 | evp of corporate strategy |
Jul 15, 2022 | schiller brigitte | acquired | - | - | 26,738 | - |
May 16, 2022 | schiller brigitte | bought | 12,375 | 0.825 | 15,000 | - |
Which funds bought or sold UNCY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 25, 2024 | Rosalind Advisors, Inc. | new | - | 2,593,910 | 2,593,910 | 2.42% |
Apr 22, 2024 | Vivo Capital, LLC | unchanged | - | 1,777,760 | 4,788,810 | 0.38% |
Mar 11, 2024 | VANGUARD GROUP INC | unchanged | - | 886 | 99,835 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 100 | 81,810 | 161,990 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -9,000 | - | -% |
Feb 15, 2024 | Nantahala Capital Management, LLC | added | 98.14 | 2,981,950 | 5,966,620 | 0.18% |
Feb 14, 2024 | RA CAPITAL MANAGEMENT, L.P. | unchanged | - | 26,724 | 3,011,520 | 0.05% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | 270 | 30,401 | -% |
Feb 14, 2024 | CAPTRUST FINANCIAL ADVISORS | unchanged | - | 145 | 16,313 | -% |
Unveiling Unicycive Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Unicycive Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | -8.06 | 7.03 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.0B | 2.0B | -57.25 | 9.49 | ||||
BMRN | 15.9B | 2.5B | 77.41 | 6.43 | ||||
INCY | 11.9B | 3.8B | 15.99 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.83 | 14.44 | ||||
BBIO | 5.2B | 107.9M | -9.5 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.69 | 12.99 | ||||
ARWR | 3.0B | 240.7M | -10.07 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.92 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.79 | 4.45 | ||||
NVAX | 659.2M | 983.7M | -1.21 | 0.67 | ||||
CRBP | 400.8M | 881.7K | -8.99 | 466.16 | ||||
INO | 280.7M | 4.9M | -2.08 | 57.68 | ||||
IBIO | 7.0M | 2.1M | -0.26 | 2.14 |
Unicycive Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 |
Revenue | - | - | - | - | 675 | 813 | 951 |
Operating Expenses | 6.3% | 6,313 | 5,938 | 4,322 | 4,877 | 5,325 | 6,505 |
S&GA Expenses | -19.0% | 2,080 | 2,566 | 2,055 | 1,847 | 1,485 | 1,702 |
R&D Expenses | 25.5% | 4,233 | 3,372 | 2,267 | 3,030 | 3,840 | 4,803 |
Interest Expenses | 8.3% | 20.00 | 18.00 | 32.00 | 12.00 | 3.00 | 3.00 |
Net Income | -80.0% | -7,798 | -4,333 | -3,838 | -14,575 | -5,328 | -5,557 |
Net Income Margin | -19.9% | -45.25* | -37.73* | -36.04* | -32.99* | -18.99* | - |
Free Cashflow | -0.4% | -4,439 | -4,422 | -5,502 | -3,920 | -6,084 | -3,563 |
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -27.0% | 14.00 | 19.00 | 23.00 | 27.00 | 3.00 | 10.00 | 13.00 | 16.00 | 19.00 | 20.00 | - | - |
Current Assets | -27.8% | 13.00 | 19.00 | 22.00 | 26.00 | 3.00 | 10.00 | 13.00 | 15.00 | 18.00 | 20.00 | 1.00 | 0.00 |
Cash Equivalents | -32.4% | 10.00 | 14.00 | 19.00 | 24.00 | 0.00 | 7.00 | 11.00 | 14.00 | 17.00 | 18.00 | 0.00 | - |
Net PPE | -7.1% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Liabilities | 12.4% | 18.00 | 16.00 | 16.00 | 17.00 | 3.00 | 6.00 | 3.00 | 3.00 | 2.00 | 1.00 | 5.00 | 3.00 |
Current Liabilities | 13.4% | 18.00 | 15.00 | 15.00 | 16.00 | 3.00 | 6.00 | 3.00 | 2.00 | 2.00 | 1.00 | 5.00 | 3.00 |
Shareholder's Equity | -212.4% | -3.81 | 3.00 | - | - | -0.47 | 5.00 | 10.00 | 13.00 | 16.00 | 19.00 | - | - |
Retained Earnings | -13.7% | -64.50 | -56.74 | -52.41 | -48.57 | -34.00 | -28.67 | -23.11 | -19.48 | -15.94 | -13.19 | -7.99 | -5.92 |
Additional Paid-In Capital | 1.0% | 61.00 | 60.00 | 33.00 | 33.00 | 34.00 | 33.00 | 33.00 | 33.00 | 32.00 | 32.00 | 4.00 | 3.00 |
Shares Outstanding | 0.0% | 35.00 | 35.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 14.00 | 9.00 | 9.00 |
Float | - | - | - | 20.00 | - | - | - | 12.00 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -0.4% | -4,439 | -4,422 | -5,502 | -3,920 | -6,084 | -3,563 | -3,047 | -2,957 | -1,403 | -3,474 | -217 | -673 | - | - | - |
Share Based Compensation | -40.8% | 550 | 929 | 144 | 144 | 197 | 266 | 294 | 290 | 231 | 239 | 294 | 202 | 71.00 | 71.00 | 60.00 |
Cashflow From Investing | - | - | - | - | - | - | - | - | -2.00 | - | - | - | - | - | - | - |
Cashflow From Financing | -302.0% | -205 | -51.00 | - | 27,797 | - | - | - | - | - | 21,484 | 71.00 | 820 | - | - | - |
Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Licensing revenues | $ 675 | $ 951 |
Operating expenses: | ||
Research and development | 12,902 | 12,436 |
General and administrative | 8,547 | 6,567 |
Total operating expenses | 21,449 | 19,003 |
Loss from operations | (20,774) | (18,052) |
Other income (expenses): | ||
Interest income | 615 | |
Interest expense | (82) | (6) |
Change in fair value of warrants | (10,303) | |
Total other income (expenses) | (9,770) | (6) |
Net loss | (30,544) | (18,058) |
Deemed dividend to Series A-1 preferred stockholders | (867) | |
Net loss attributable to common stockholders | $ (31,411) | $ (18,058) |
Net loss per share attributable to common stockholders, basic (in Dollars per share) | $ (1.28) | $ (1.2) |
Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) | 24,539,309 | 15,057,049 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash | $ 9,701 | $ 455 |
Prepaid expenses and other current assets | 3,698 | 2,189 |
Total current assets | 13,399 | 2,644 |
Right of use asset, net | 766 | 152 |
Property, plant and equipment, net | 26 | 22 |
Total assets | 14,191 | 2,818 |
Current liabilities: | ||
Accounts payable | 839 | 892 |
Accrued liabilities | 3,234 | 2,237 |
Warrant liability | 13,134 | |
Operating lease liability – current | 327 | 155 |
Total current liabilities | 17,534 | 3,284 |
Operating lease liability – long term | 466 | |
Total liabilities | 18,000 | 3,284 |
Commitments and contingencies (Note 8) | ||
Stockholders’ deficit: | ||
Preferred stock value | ||
Common stock, $0.001 par value per share – 200,000,000 shares authorized at December 31, 2022 and September 30, 2023; 15,231,655 shares issued and outstanding at December 31, 2022, and 34,754,401 shares issued and outstanding at September 30, 2023 | 35 | 15 |
Additional paid-in capital | 60,697 | 33,516 |
Accumulated deficit | (64,541) | (33,997) |
Total stockholders’ deficit | (3,809) | (466) |
Total liabilities and stockholders’ deficit | 14,191 | 2,818 |
Series A-2 Preferred Stock | ||
Stockholders’ deficit: | ||
Preferred stock value |